Sun L, Yoshii Y, Miyagi K, Ishida A
Department of Neurosurgery, School of Medicine, University of the Ryukyus, Okinawa, Japan.
No Shinkei Geka. 1999 Feb;27(2):119-25.
The antitumor effects of vitamin K2 were studied using three glioma cell lines: C6 (rat glioma cell), RBR17T and T98G (human glioma cell). The antitumor effects were estimated by count assay. The results was that vitamin K2 induced growth inhibition in a dose-dependent manner. The RBR 17T cells exposed to vitamin K2 for 72 hours resulted in oligonucleosomal DNA fragmentation and formed a ladder on agarose gel electrophoresis. Furthermore, the RBR17T cells exposed to vitamin K2 for 24 hours were significantly accumulated in the G0G1 phase of the cell cycle. Those results suggested that vitamin K2 can inhibit the proliferation of cells through the induction of cell cycle arrest and apoptosis for tumor cells. The combined treatment of vitamin K2 with ACNU or 5-FU or INF-beta or 1,25-dihydroxyvitamin D3 enhanced growth inhibition significantly. In conclusion, vitamin K2 can be a useful drug for the treatment of glioma.
使用三种胶质瘤细胞系研究了维生素K2的抗肿瘤作用：C6（大鼠胶质瘤细胞）、RBR17T和T98G（人胶质瘤细胞）。通过计数分析评估抗肿瘤作用。结果是维生素K2以剂量依赖性方式诱导生长抑制。暴露于维生素K2 72小时的RBR 17T细胞导致寡核小体DNA片段化，并在琼脂糖凝胶电泳上形成梯状条带。此外，暴露于维生素K2 24小时的RBR17T细胞在细胞周期的G0G1期显著积累。这些结果表明，维生素K2可通过诱导肿瘤细胞的细胞周期停滞和凋亡来抑制细胞增殖。维生素K2与ACNU或5-FU或INF-β或1,25-二羟基维生素D3联合治疗可显著增强生长抑制作用。总之，维生素K2可能是一种治疗胶质瘤的有用药物。
